ArticleJournal of gastrointestinal oncology2026
A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive colorectal cancer (oCRC) correlates with advanced disease and poor outcomes. This study aimed to identify independent prognostic factors using clinical and laboratory data and construct a predictive nomogram for oCRC patients' individualized survival estimation and clinical decision-making. Methods: A retrospective cohort of 167 patients with histologically confirmed oCRC admitted to hospital between February 2019 and February 2021 was analyzed. Patients were randomly divided into a training cohort (n=116) and a validation cohort (n=51) in a 7:3 ratio. Prognostic variables were identified using univariate and multivariate Cox proportional hazards regression analyses. A nomogram was developed based on independent prognostic factors. Model performance was assessed using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA) to evaluate its discrimination, calibration, and clinical utility, respectively. Results: Multivariate Cox regression analysis identified five independent prognostic factors: M stage [hazard ratio (HR) =1.917, 95% confidence interval (CI): 1.005-3.657, P=0.048], tumor grade (HR =0.229, 95% CI: 0.096-0.543, P<0.001), carbohydrate antigen 19-9 (CA19-9; HR =3.919, 95% CI: 2.038-7.538, P<0.001), albumin-to-globulin ratio (AGR; HR =2.103, 95% CI: 1.158-3.817, P=0.02), and platelet-to-lymphocyte ratio (PLR; HR =1.873, 95% CI: 1.013-3.464, P=0.045). These variables were incorporated into a prognostic nomogram. The model demonstrated good discriminatory ability, with area under the curve (AUC) values of 0.721 in the training cohort and 0.776 in the validation cohort. Additionally, the model exhibited satisfactory calibration and clinical utility, as evidenced by DCA. Conclusions: The nomogram (incorporating M stage, tumor grade, CA19-9, AGR, PLR) provides individualized prognosis for oCRC patients, and may aid clinical risk stratification and therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.